News

Intercell in €25m finance deal with BB Biotech
Enlarge image

BusinessAustriaSwitzerland

Intercell in €25m finance deal with BB Biotech

09.05.2012 - Austrian biotech company Intercell AG has signed a €25m financing deal with Swiss investor BB BiotechAG.

Vienna  – The vaccine maker also said it is in talks with other investors   concerning a private stock placement that could total €15m. The  investment, through a fully owned subsidiary of BB Biotech AG, consists of a €20m secured loan and a commitment to invest €5m as part  of a proposed private share placement. Intercell’s CEO, Thomas Lingelbach, stated: “Following the successful strategic resetting in  2011, this financing marks an important step in the renewal of  Intercell as a notable biotech vaccine company. With growing sales  from our first product on the market, a diversified pipeline and  technology base and a disciplined financial strategy, we are now very  well positioned for the next development phase of our company.”

Intercell is trying to get back on track after several product setbacks sparked worries about its pipeline prospects. After a setback  in the development of a traveller’s diarrhoea vaccine last year, the  new focus of the company is on vaccines preventing nosocomial  infections. The secured six-year loan carries a variable interest  rate. Intercell will pay BB Biotech royalties on sales revenues from  its product Ixiaro, a vaccine for Japanese encephalitis. The €5m  equity investment will see BB Biotech subscribe for nearly 2 million  Intercell shares for about 2.55 € per share as part of the private  placement. According to Intercell,  existing shareholders will not get  subscription rights for the placement

http://www.european-biotechnology-news.com/news/news/2012-02/intercell-in-eur25m-finance-deal-with-bb-biotech.html

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes over to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • IMMUNICUM AB (S)29.80 SEK12.88%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • BIONOR PHARMA (N)0.73 NOK-7.59%
  • ACTIVE BIOTECH (S)10.20 SEK-5.12%

TOP

  • AB SCIENCE (F)17.91 EUR62.8%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.19 EUR36.9%

FLOP

  • THERAMETRICS (CH)0.02 CHF-50.0%
  • SERODUS (N)1.41 NOK-31.2%
  • OREXO (S)48.80 SEK-21.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.50 SEK1974.8%
  • NICOX (F)8.88 EUR369.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.6%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.65 EUR-76.5%

No liability assumed, Date: 02.05.2016